用新型破膜化合物对抗MRSA
公共卫生行政人员越来越关注耐甲氧西林金黄色葡萄球菌(MRSA)。该细菌已经对不少治疗产生了耐药性，甚至在某些情况下连最后手段的抗生素也未能幸免。如今，据美国化学学会《结合物化学》杂志报道，研究人员开发出一种新的化合物，可以治疗无急性中毒症状小鼠的耐甲氧西林金黄色葡萄球菌皮肤感染。并且多次用药后，也没有产生耐药性的迹象。据美国疾病控制和预防中心通报，美国每年至少有200万人感染耐药菌，其中23000人死于这些感染。多年来，研究人员一直在努力与这一重大的公共健康威胁作斗争。在这场战争中，最新阵线之一是抗菌肽及脂肽,它们可破坏细菌的细胞膜。但是，将这些分子转化为临床药品却非常困难。
最近，研究人员已经开发出一种新型破膜化合物——LANAs，在实验室测试中，LANAs已经能够有效地杀死某些细菌和埃博拉病毒。Mohini Mohan Konai和Jayanta Haldar希望进一步证明这些化合物对耐甲氧西林金黄色葡萄球菌也同样有效。
研究人员发现，LANAs在实验室的实验中对四种耐甲氧西林金黄色葡萄球菌菌株有效。小鼠试验表明，这种化合物可以消除耐甲氧西林金黄色葡萄球菌（MRSA）皮肤感染，尽管MRSA形成的难治性生物膜早已臭名昭著。即使经过20次传代，耐甲氧西林金黄色葡萄球菌也对这种破膜化合物产生耐药。研究人员称：结果表明， LANAs可能是治疗耐甲氧西林金黄色葡萄球菌皮肤感染“强力竞争者”。资料来源：美国化学学会
Fighting MRSA With New Membrane-Busting Compounds
Public health officials are increasingly concerned over methicillin-resistant Staphylococcus aureus (MRSA). The bacteria have developed resistance to a number of treatments, even antibiotics of last resort in some cases. Now researchers report in ACS' journal Bioconjugate Chemistry that a new class of compounds can treat MRSA skin infections in mice with no signs of acute toxicity, and no signs that the bacteria would develop resistance to them after many applications.
According to the U.S. Centers for Disease Control and Prevention, every year at least 2 million people inAmericabecome infected by bacteria resistant to antibiotics, and 23,000 people die from such infections. Researchers have been working to combat this major public health threat for years. One of the latest fronts in this fight involves antimicrobial peptides and lipopeptides, which can destroy bacterial membranes. But translating these molecules into clinical products has been difficult. More recently, researchers have developed a new class of membrane-busting compounds called lysine-conjugated aliphatic norspermidine analogues (LANAs) that have been effective at killing certain bacteria and the Ebola virus in lab tests. Mohini Mohan Konai and Jayanta Haldar wanted to see if these compounds could also work against MRSA.
The researchers found that LANAs were effective against four MRSA strains in lab experiments. Testing on mice showed that the compounds could eliminate MRSA skin infections, which form notoriously difficult-to-treat biofilms. Even after 20 passages, the MRSA bacteria failed to develop resistance to the compounds. The results suggest that LANAs could be strong contenders for treating MRSA skin infections, the researchers say.
The authors cite funding from the Jawaharlal Nehru Centre for Advanced Scientific Research. They also acknowledge the Council of Scientific and Industrial Research (India) for support via a senior research fellowship.
Source: American Chemical Society
用新型破膜化合物对抗MRSA，这是个好消息 ，可以对付MRSA了！ 新型破膜化合物对抗MRSA，有找到了新途径。
页:
[1]